Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

NCT02274766 is registered in ClinicalTrials.gov with Adamas Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02274766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02274766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)
Lead sponsor
Adamas Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
March 10, 2016
Enrollment
77 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

dyskinesia, levodopa-induced dyskinesia (lid), parkinson's disease (pd)